Evidence that tirzepatide protects against diabetes-related cardiac damages

Fatemeh Taktaz,Lucia Scisciola,Rosaria Anna Fontanella,Ada Pesapane,Puja Ghosh,Martina Franzese,Giovanni Tortorella,Armando Puocci,Eduardo Sommella,Giuseppe Signoriello,Fabiola Olivieri,Michelangela Barbieri,Giuseppe Paolisso
DOI: https://doi.org/10.1186/s12933-024-02203-4
IF: 8.949
2024-04-01
Cardiovascular Diabetology
Abstract:Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE), their impact on heart failure (HF) remains unclear. Therefore, our study examined the cardioprotective effects of tirzepatide (TZT), a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist.
cardiac & cardiovascular systems,endocrinology & metabolism
What problem does this paper attempt to address?